Ebola

Ervebo has been approved for the prevention of Ebola virus disease, caused by Zaire ebolavirus in individuals 18 years of age and older.

Ebola vaccines could be given as an emergency intervention to individuals exposed to the virus.

The PALM trial evaluated the safety and efficacy of several experimental treatments for Ebola in the Democratic Republic of Congo.

Investigators now think that Ebola prevention methods should be a top priority moving forward.

Prequalification status indicates that the vaccine meets the WHO’s standard for efficacy, safety, and quality.

Since 2014 NYC Health + Hospitals has worked to maintain preparedness against diseases like Ebola.

Leaders from the WHO and various impacted countries met to assess the risks of the Ebola outbreak in the Democratic Republic of the Congo and the future of the outbreak response.

Scientists from the National Institutes of Health are hopeful that diluting a dose of the VSV vaccine could be efficacious and stretch vaccine supplies even further.

A patient was evaluated for Ebola in a Swedish hospital. Here's what we should take away from it.

The analysis of the survey responses found a statistically significant association in denial of the biomedical discourse and dissatisfaction or mistrust of the Ebola response as indicators of social resistance.

In part 2 of our Q&A with Fair, we talk about the challenges ahead in the fight against Ebola in the Democratic Republic of the Congo.

In part 1 of our Q&A with Fair, we talk about his background, education, and experience, and also how the outbreak response to the current Ebola outbreak in the DRC differs from traditional disaster response.

The vaccine, manufactured by Johnson & Johnson, is administered in 2 doses, 56 days apart and will be used in areas that are not experiencing active transmission.

In this outbreak, 18% of Ebola cases have been tied to health care transmission. How can we prevent this from continuing?

The target action date for the V920 investigational Ebola vaccine is set for March 14, 2020.

Investigators observed that, when compared with the general population of Guinea, survivors of Ebola had a 5-fold increased risk of mortality over a mean of 1 year of follow-up after discharge.

The Biomedical Advanced Research and Development Authority will contribute $23 million for Merck to continue manufacturing the Ebola vaccine over the next year.

Variances in collection and siloed efforts are hurting this outbreak response.

The research team deciphered that the nitazoxanide boosts the ability of specific viral sensors to detect Ebola when infected, which then sparks an antiviral immune response.

An independent monitoring board recommended early termination of the PALM trial after determining that 2 of the 4 experimental therapies were linked with better rates of survival.

The Ad26.ZEBOV, MVA-BN-Filo vaccine regimen will be evaluated in an open-label, single-arm study of 800 participants, including frontline health care workers.

August 1, 2019, marks the 1 year anniversary of the North Kivu Ebola outbreak.

From vaccines to conflict, here's an update on why this Ebola outbreak is so unique.

Dr. Tedros has accepted the World Health Organization (WHO) International Health Regulations Emergency Committee's recommendation.

The Congolese city is home to more than 2 million people and rests against the border of Rwanda, a nation that is potentially vulnerable to the spread of Ebola.

A new matrix will help prepare multiple industries to combat potential Ebola occupational exposures

The neighboring nation to the DRC has also launched ring vaccination following the confirmation of 3 travel-associated Ebola cases.

This case is the first confirmed case of Ebola that Uganda has detected during the ongoing outbreak in the neighboring Democratic Republic of the Congo.

As the DRC records 2000 cases of Ebola, Contagion® spoke with Krutika Kuppalli, MD, about how this outbreak is unique and whether there is an end in sight.

The latest on this ever-changing and complex outbreak.